Morphogen-IX: Morphogen-IX announces appointment of CEO and SAB members

Morphogen-IX Ltd, a preclinical biotechnology company focused on the development of bone morphogenetic proteins for the treatment of pulmonary arterial hypertension (PAH), has announced the appointment of Professor Nick Morrell as CEO. Morrell co-founded the company in 2015 based on research from his lab at the University of Cambridge.